Portal de Periódicos da CAPES

Robustness of Free Prostate Specific Antigen Measurements to Reduce Unnecessary Biopsies in the 2.6 to 4.0 ng./ml. Range

2002; Lippincott Williams & Wilkins; Volume: 168; Issue: 3 Linguagem: Inglês

10.1016/s0022-5347(05)64543-0

1527-3792

Kimberly A. Roehl, Jo Ann V. Antenor, William J. Catàlona,

Statistical Methods in Clinical Trials

No AccessJournal of UrologyCLINICAL UROLOGY: ORIGINAL ARTICLES1 Sep 2002Robustness of Free Prostate Specific Antigen Measurements to Reduce Unnecessary Biopsies in the 2.6 to 4.0 ng./ml. Range Kimberly A. Roehl, Jo ANN V. Antenor, and William J. Catalona Kimberly A. RoehlKimberly A. Roehl , Jo ANN V. AntenorJo ANN V. Antenor , and William J. CatalonaWilliam J. Catalona View All Author Informationhttps://doi.org/10.1016/S0022-5347(05)64543-0AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: Prostate specific antigen (PSA) cutoffs lower than 4.0 ng./ml. are being evaluated more frequently but lower PSA cutoffs increase the number of prostatic biopsies. PSA exists in several forms free and complexed to proteins. Percent free PSA is lower in men with prostate cancer. Accordingly, free PSA and complexed PSA have been used to distinguish between cancer and benign disease in the diagnostic gray zone of 4 to 10 ng./ml. to eliminate unnecessary biopsies. There are limited data on the robustness of free PSA measurements in the 2.6 to 4.0 ng./ml. total PSA range. Materials and Methods: We evaluated percent free PSA measurements to discriminate between cancer and benign conditions in 965 consecutive volunteers in a prostate cancer screening study who underwent prostatic biopsy for a PSA of 2.6 to 4.0 ng./ml. and had benign digital rectal examination. Results: Overall 25% of men had cancer detected. A 25% free PSA cutoff detected 85% of cancers and avoided 19% of negative (cancer-free) biopsies, while a 30% free PSA cutoff detected 93% of cancers and avoided only 9% of negative biopsies. Of those men who underwent radical prostatectomy 132 (80%) had pathologically organ confined tumors. Only 5% of these tumors fulfilled the published pathological criteria for possibly clinically unimportant tumors. Conclusions: Percent free PSA provides risk assessment but does not eliminate many unnecessary prostatic biopsies while maintaining a high sensitivity in the narrow total PSA range of 2.6 to 4.0 ng./ml. References 1 : Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL benign prostate examination. Enhancement of specificity with free PSA measurements. JAMA1997; 277: 1452. Crossref, Medline, Google Scholar 2 : Tumor characteristics in screening for prostate cancer with without rectal examination as an initial screening test at low PSA (0.–3.9 ng/ml). Prostate2001; 47: 252. Crossref, Medline, Google Scholar 3 : The incidence of prostate cancer in a screening population with a serum prostate specific antigen between 2. 4.0 ng/ml: relation to biopsy strategy. J Urol2001; 165: 757. Link, Google Scholar 4 : Evaluation of prostatic specific antigen digital rectal examination as screening tests for prostate cancer. Prostate2000; 45: 19. Crossref, Medline, Google Scholar 5 : Use of lower prostate specific antigen cutoffs for prostate cancer screening in black white men. J Urol1998; 160: 1734. Link, Google Scholar 6 : Enzymatic activity of prostate-specific antigen its reactions with extracellular serine proteinase inhibitors. Eur J Biochem1990; 194: 755. Crossref, Medline, Google Scholar 7 : Prostate-specific antigen in serum occurs predominantly in complex with alpha-1 antichymotrypsin. Clin Chem1991; 37: 1618. Crossref, Medline, Google Scholar 8 : Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA1998; 279: 1542. Crossref, Medline, Google Scholar 9 : Correlation of percent free PSA pathologic features of prostatic carcinomas. J Urol1996; 155: 415A. Google Scholar 10 : Percentage of free prostate-specific antigen in sera predicts aggressiveness of prostate cancer a decade before diagnosis. Urology1997; 49: 379. Crossref, Medline, Google Scholar 11 : Percentage of free serum prostate-specific antigen as a predictor of pathologic features of prostate cancer in a screening population. Urology1998; 51: 558. Crossref, Medline, Google Scholar 12 : The use of percent free prostate specific antigen for staging clinically localized prostate cancer. J Urol1998; 159: 1238. Link, Google Scholar 13 : Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA1995; 274: 1214. Crossref, Medline, Google Scholar 14 : Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA1993; 270: 948. Crossref, Medline, Google Scholar 15 : Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med1991; 324: 1156. Crossref, Medline, Google Scholar 16 : Longitudinal screening for prostate cancer with prostate-specific antigen. JAMA1996; 276: 1309. Crossref, Medline, Google Scholar 17 : Nonpalpable stage T1c prostate cancer: prediction of insignificant disease using free/total prostate specific antigen levels needle biopsy findings. J Urol1998; 160: 2407. Link, Google Scholar 18 : A multicenter study on the detection of prostate cancer by digital rectal examination prostate-specific antigen in men with or without urinary symptoms. Eur Urol1997; 32: 133. Crossref, Medline, Google Scholar 19 : Prostate cancer detection in Black White men with abnormal digital rectal examination prostate specific antigen less than 4 ng./ml. J Urol2000; 164: 1961. Link, Google Scholar 20 : Development of a nomogram that predicts the probability of a positive prostate biopsy in men with an abnormal digital rectal examination a prostate-specific antigen between 0 4 ng/mL. Urology1999; 54: 709. Crossref, Medline, Google Scholar 21 : Pathologic clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA1994; 271: 368. Crossref, Medline, Google Scholar 22 : A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA1995; 273: 289. Crossref, Medline, Google Scholar 23 : Free to total prostate-specific antigen (PSA) ratio improves the discrimination between prostate cancer benign prostatic hyperplasia (BPH) in the diagnostic gray zone of 1. to 10.0 ng/mL total PSA. Urology1996; 48: 67. Crossref, Medline, Google Scholar 24 : Ratio of free or complexed prostate-specific antigen (PSA) to total PSA: which ratio improves differentiation between benign prostatic hyperplasia prostate cancer?. Clin Chem2000; 46: 55. Crossref, Medline, Google Scholar 25 : Molecular forms of prostate-specific antigen in serum with concentrations of total prostate-specific antigen <4 microg/L: are they useful tools for early detection screening of prostate cancer?. Int J Cancer2001; 93: 759. Crossref, Medline, Google Scholar 26 : A truncated precursor form of prostate-specific antigen is a more specific serum marker of prostate cancer. Cancer Res2001; 61: 6958. Medline, Google Scholar From the Division of Urologic Surgery, Department of Surgery, Washington University School of Medicine, St. Louis, Missouri© 2002 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited by Huang Z, Zhang L, Yi X and Yu X (2015) Diagnostic and prognostic values of tissue hsa-miR-30c and hsa-miR-203 in prostate carcinomaTumor Biology, 10.1007/s13277-015-4262-9, VOL. 37, NO. 4, (4359-4365), Online publication date: 1-Apr-2016. van Velthoven R, Aoun F, Marcelis Q, Albisinni S, Zanaty M, Lemort M, Peltier A and Limani K (2015) A prospective clinical trial of HIFU hemiablation for clinically localized prostate cancerProstate Cancer and Prostatic Diseases, 10.1038/pcan.2015.55, VOL. 19, NO. 1, (79-83), Online publication date: 1-Mar-2016. Wu C, Lin H, Wang C, Lu L, Yu T, Hung W, Houng J, Chung F, Lee Y and Hu J (2015) Evaluation of a rapid quantitative determination method of PSA concentration with gold immunochromatographic stripsBMC Urology, 10.1186/s12894-015-0105-7, VOL. 15, NO. 1, Online publication date: 1-Dec-2015. Hermanns T, Kuk C and Zlotta A (2015) Clinical Presentation, Diagnosis and Staging Urological Oncology, 10.1007/978-0-85729-482-1_40, (697-717), . Yang Q, Zheng Y and Zhu D (2014) Diagnostic performance of microRNAs expression in prostate cancerTumor Biology, 10.1007/s13277-014-2351-9, VOL. 35, NO. 10, (10529-10538), Online publication date: 1-Oct-2014. Stephan C, Ralla B and Jung K (2014) Prostate-specific antigen and other serum and urine markers in prostate cancerBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 10.1016/j.bbcan.2014.04.001, VOL. 1846, NO. 1, (99-112), Online publication date: 1-Aug-2014. Tempany C and Fichtinger G (2014) MR Imaging and the Biopsy of Prostate Cancer Intraoperative Imaging and Image-Guided Therapy, 10.1007/978-1-4614-7657-3_56, (739-756), . Kim J, Shim J, Bae J, Park H, Moon D, Kwon S and Park J (2013) Association between percent-free prostate-specific antigen and glomerular filtration rate in transrectal ultrasound-guided biopsy-proven patients with prostate-specific antigen levels ranging from 4 to 10 ng/mlWorld Journal of Urology, 10.1007/s00345-012-1012-0, VOL. 31, NO. 2, (313-318), Online publication date: 1-Apr-2013. Martínez-Amores Martínez B, Durán Poveda M, Sánchez Encinas M and Molina Villaverde R (2013) Actualización en cáncer de próstataMedicine - Programa de Formación Médica Continuada Acreditado, 10.1016/S0304-5412(13)70509-2, VOL. 11, NO. 26, (1578-1587), Online publication date: 1-Feb-2013. Nepple K, Sandhu G and Kibel A (2013) Percent Free PSA Prostate Cancer Diagnosis, 10.1007/978-1-62703-188-2_5, (51-60), . Chen Z, Zhang G, Li H, Luo J, Li Z, Chen G and Yang J (2012) A panel of five circulating microRNAs as potential biomarkers for prostate cancerThe Prostate, 10.1002/pros.22495, VOL. 72, NO. 13, (1443-1452), Online publication date: 15-Sep-2012. Anderson-Jackson L, McGrowder D and Alexander-Lindo R (2012) Prostate Specific Antigen and Gleason Score in Men with Prostate Cancer at a Private Diagnostic Radiology Centre in Western JamaicaAsian Pacific Journal of Cancer Prevention, 10.7314/APJCP.2012.13.4.1453, VOL. 13, NO. 4, (1453-1456), Online publication date: 30-Apr-2012. Loeb S and Carter H (2012) Early Detection, Diagnosis, and Staging of Prostate Cancer Campbell-Walsh Urology, 10.1016/B978-1-4160-6911-9.00099-2, (2763-2770.e7), . Lee B, Moussa A, Li J, Fareed K and Jones J (2011) Percentage of Free Prostate-specific Antigen: Implications in Modern Extended Scheme Prostate BiopsyUrology, 10.1016/j.urology.2010.06.072, VOL. 77, NO. 4, (899-903), Online publication date: 1-Apr-2011. Reis L, Zani E, Alonso J, Simões F, Rejowski R and Ferreira U (2011) ¿Impacta el criterio para indicar la biopsia prostática sobre su exactitud? Estudio prospectivo llevado a cabo sobre una población de pacientes ambulantesActas Urológicas Españolas, 10.1016/j.acuro.2010.06.011, VOL. 35, NO. 1, (10-14), Online publication date: 1-Jan-2011. Reis L, Zani E, Alonso J, Simões F, Rejowski R and Ferreira U (2011) Does the criterion for prostate biopsy indication impact its accuracy? A prospective population-based outpatient clinical setting studyActas Urológicas Españolas (English Edition), 10.1016/S2173-5786(11)70004-X, VOL. 35, NO. 1, (10-14), Online publication date: 1-Jan-2011. Ploussard G, Haese A, Van Poppel H, Marberger M, Stenzl A, Mulders P, Huland H, Bastien L, Abbou C, Remzi M, Tinzl M, Feyerabend S, Stillebroer A, Van Gils M, Schalken J and De La Taille A (2010) The prostate cancer gene 3 (PCA3) urine test in men with previous negative biopsies: does free-to-total prostate-specific antigen ratio influence the performance of the PCA3 score in predicting positive biopsies?BJU International, 10.1111/j.1464-410X.2010.09286.x, VOL. 106, NO. 8, (1143-1147), Online publication date: 1-Oct-2010. Le B, Griffin C, Loeb S, Carvalhal G, Kan D, Baumann N and Catalona W (2010) [-2]Proenzyme Prostate Specific Antigen is More Accurate Than Total and Free Prostate Specific Antigen in Differentiating Prostate Cancer From Benign Disease in a Prospective Prostate Cancer Screening StudyJournal of Urology, VOL. 183, NO. 4, (1355-1359), Online publication date: 1-Apr-2010. Park S and Lee H (2010) What Are Some New Developments in Prostate Cancer Diagnosis?Journal of the Korean Medical Association, 10.5124/jkma.2010.53.2.107, VOL. 53, NO. 2, (107), . Walz J, Haese A, Scattoni V, Steuber T, Chun F, Briganti A, Montorsi F, Graefen M, Huland H and Karakiewicz P (2008) Percent free prostate-specific antigen (PSA) is an accurate predictor of prostate cancer risk in men with serum PSA 2.5 ng/mL and lowerCancer, 10.1002/cncr.23885, VOL. 113, NO. 10, (2695-2703), Online publication date: 15-Nov-2008. Stephan C, Cammann H, Meyer H, Müller C, Deger S, Lein M and Jung K (2008) An artificial neural network for five different assay systems of prostate-specific antigen in prostate cancer diagnosticsBJU International, 10.1111/j.1464-410X.2008.07765.x, VOL. 102, NO. 7, (799-805), Online publication date: 1-Oct-2008. Alapont Alacreu J, Navarro Rosales S, Budía Alba A, España Furió F, Morera Martínez F and Jiménez Cruz J (2008) PSA y hK2 en el diagnóstico de cáncer de próstataActas Urológicas Españolas, 10.1016/S0210-4806(08)73891-9, VOL. 32, NO. 6, (575-588), Online publication date: 1-Jan-2008. Nargund V (2008) Clinical Presentation, Diagnosis, and Staging Urological Oncology, 10.1007/978-1-84628-738-1_26, (470-481), . Stephan C, Jung K, Lein M and Diamandis E (2007) PSA and other tissue kallikreins for prostate cancer detectionEuropean Journal of Cancer, 10.1016/j.ejca.2007.06.006, VOL. 43, NO. 13, (1918-1926), Online publication date: 1-Sep-2007. Stephan C, Cammann H, Meyer H, Lein M and Jung K (2007) PSA and new biomarkers within multivariate models to improve early detection of prostate cancerCancer Letters, 10.1016/j.canlet.2006.12.031, VOL. 249, NO. 1, (18-29), Online publication date: 1-Apr-2007. Benchikh El Fegoun A and Villers A (2007) Les formes moléculaires du PSAProgrès en Urologie, 10.1016/S1166-7087(07)92255-1, VOL. 17, NO. 2, (165-171), Online publication date: 1-Apr-2007. Stephan C, Xu C, Cammann H, Graefen M, Haese A, Huland H, Semjonow A, Diamandis E, Remzi M, Djavan B, Wildhagen M, Blijenberg B, Finne P, Stenman U, Jung K and Meyer H (2007) Assay-specific artificial neural networks for five different PSA assays and populations with PSA 2–10 ng/ml in 4,480 menWorld Journal of Urology, 10.1007/s00345-006-0132-9, VOL. 25, NO. 1, (95-103), Online publication date: 15-Mar-2007. Jung K, Hoesel W, Reiche J, Deger S, Kramer J, Loening S, Lein M and Stephan C (2007) Electrophoretic Subforms of Free Prostate-Specific Antigen in Serum as Promising Diagnostic Tool in Prostate Cancer DiagnosticsUrology, 10.1016/j.urology.2006.09.066, VOL. 69, NO. 2, (320-325), Online publication date: 1-Feb-2007. Loeb S, Roehl K, Yu X, Han M and Catalona W (2007) Use of Prostate-Specific Antigen Velocity to Follow Up Patients with Isolated High-Grade Prostatic Intraepithelial Neoplasia on Prostate BiopsyUrology, 10.1016/j.urology.2006.09.040, VOL. 69, NO. 1, (108-112), Online publication date: 1-Jan-2007. STEPHAN C, JUNG K, NAKAMURA T, YOUSEF G, KRISTIANSEN G and DIAMANDIS E (2006) Serum human glandular kallikrein 2 (hK2) for distinguishing stage and grade of prostate cancerInternational Journal of Urology, 10.1111/j.1442-2042.2006.01276.x, VOL. 13, NO. 3, (238-243), Online publication date: 1-Mar-2006. Bostwick D, Gould V, Qian J, Susani M and Marberger M (2006) Prostate cancer detected by uPM3: radical prostatectomy findingsModern Pathology, 10.1038/modpathol.3800583, VOL. 19, NO. 5, (630-633), . Haker S, Mulkern R, Roebuck J, Barnes A, DiMaio S, Hata N and Tempany C (2005) Magnetic Resonance-guided Prostate InterventionsTopics in Magnetic Resonance Imaging, 10.1097/00002142-200510000-00003, VOL. 16, NO. 5, (355-368), Online publication date: 1-Oct-2005. Miano R, Mele G, Germani S, Bove P, Sansalone S, Pugliese P and Micali F (2005) Evaluation of a new, rapid, qualitative, one-step PSA Test for prostate cancer screening: the PSA RapidScreen testProstate Cancer and Prostatic Diseases, 10.1038/sj.pcan.4500802, VOL. 8, NO. 3, (219-223), Online publication date: 1-Sep-2005. Kravchick S, Peled R, Dorfman D, Agulansky L, Ben-Dor D and Cytron S (2005) Predictive criteria for prostate cancer detection in men with serum PSA concentration of 2.0 to 4.0 ng/mLUrology, 10.1016/j.urology.2005.04.012, VOL. 66, NO. 3, (542-546), Online publication date: 1-Sep-2005. Roddam A, Duffy M, Hamdy F, Ward A, Patnick J, Price C, Rimmer J, Sturgeon C, White P and Allen N (2005) Use of Prostate-Specific Antigen (PSA) Isoforms for the Detection of Prostate Cancer in Men with a PSA Level of 2–10 ng/ml: Systematic Review and Meta-AnalysisEuropean Urology, 10.1016/j.eururo.2005.04.015, VOL. 48, NO. 3, (386-399), Online publication date: 1-Sep-2005. Moul J (2005) A discussion of general prostate cancer screening versus targeted diagnosis in younger menCurrent Prostate Reports, 10.1007/s11918-005-0002-8, VOL. 3, NO. 3, (99-111), Online publication date: 1-Sep-2005. Stephan C, Stroebel G, Heinau M, Lenz A, Roemer A, Lein M, Schnorr D, Loening S and Jung K (2005) The ratio of prostate-specific antigen (PSA) to prostate volume (PSA density) as a parameter to improve the detection of prostate carcinoma in PSA values in the range of < 4 ng/mLCancer, 10.1002/cncr.21267, VOL. 104, NO. 5, (993-1003), Online publication date: 1-Sep-2005. EGGENER S, ROEHL K and CATALONA W (2018) PREDICTORS OF SUBSEQUENT PROSTATE CANCER IN MEN WITH A PROSTATE SPECIFIC ANTIGEN OF 2.6 TO 4.0 NG/ML AND AN INITIALLY NEGATIVE BIOPSYJournal of Urology, VOL. 174, NO. 2, (500-504), Online publication date: 1-Aug-2005. Sözen S, Eskicorapci S, Küpeli B, İrkilata L, Altinel M, Özer G, Uygur C, Alkibay T and Özen H (2005) Complexed Prostate Specific Antigen Density is Better Than the Other PSA Derivatives for Detection of Prostate Cancer in Men with Total PSA between 2.5 and 20ng/ml: Results of a Prospective Multicenter StudyEuropean Urology, 10.1016/j.eururo.2004.10.009, VOL. 47, NO. 3, (302-307), Online publication date: 1-Mar-2005. GJENGSTØ P, PAUS E, HALVORSEN O, EIDE J, AKSLEN L, WENTZEL-LARSEN T and HOISAETER P (2018) PREDICTORS OF PROSTATE CANCER EVALUATED BY RECEIVER OPERATING CHARACTERISTICS PARTIAL AREA INDEX: A PROSPECTIVE INSTITUTIONAL STUDYJournal of Urology, VOL. 173, NO. 2, (425-428), Online publication date: 1-Feb-2005.LOEB S, HAN M, ROEHL K, ANTENOR J and CATALONA W (2018) ACCURACY OF PROSTATE WEIGHT ESTIMATION BY DIGITAL RECTAL EXAMINATION VERSUS TRANSRECTAL ULTRASONOGRAPHYJournal of Urology, VOL. 173, NO. 1, (63-65), Online publication date: 1-Jan-2005. Jung K, Reiche J, Boehme A, Stephan C, Loening S, Schnorr D, Hoesel W and Sinha P (2004) Analysis of Subforms of Free Prostate-Specific Antigen in Serum by Two-Dimensional Gel Electrophoresis: Potential to Improve Diagnosis of Prostate CancerClinical Chemistry, 10.1373/clinchem.2004.040469, VOL. 50, NO. 12, (2292-2301), Online publication date: 1-Dec-2004. Fradet Y, Saad F, Aprikian A, Dessureault J, Elhilali M, Trudel C, Mâsse B, Piché L and Chypre C (2004) uPM3, a new molecular urine test for the detection of prostate cancerUrology, 10.1016/j.urology.2004.03.052, VOL. 64, NO. 2, (311-315), Online publication date: 1-Aug-2004. Grizzle W, Semmes O, Basler J, Izbicka E, Feng Z, Kagan J, Adam B, Troyer D, Srivastava S, Thornquist M, Zhang Z and Thompson I (2004) The early detection research network surface-enhanced laser desorption and ionization prostate cancer detection study: A study in biomarker validation in genitourinary oncologyUrologic Oncology: Seminars and Original Investigations, 10.1016/j.urolonc.2004.04.008, VOL. 22, NO. 4, (337-343), Online publication date: 1-Jul-2004. RAAIJMAKERS R, BLIJENBERG B, FINLAY J, RITTENHOUSE H, WILDHAGEN M, ROOBOL M and SCHRÖDER F (2018) PROSTATE CANCER DETECTION IN THE PROSTATE SPECIFIC ANTIGEN RANGE OF 2.0 TO 3.9 NG/ML: VALUE OF PERCENT FREE PROSTATE SPECIFIC ANTIGEN ON TUMOR DETECTION AND TUMOR AGGRESSIVENESSJournal of Urology, VOL. 171, NO. 6 Part 1, (2245-2249), Online publication date: 1-Jun-2004. Boccon-Gibod L, Djavan B, Hammerer P, Hoeltl W, Kattan M, Prayer-Galetti T, Teillac P and Tunn U (2004) Management of prostate-specific antigen relapse in prostate cancer: A European consensusInternational Journal of Clinical Practice, 10.1111/j.1368-5031.2004.00184.x, VOL. 58, NO. 4, (382-390) Han M, Gann P and Catalona W (2004) Prostate-specific antigen and screening for prostate cancerMedical Clinics of North America, 10.1016/S0025-7125(03)00188-3, VOL. 88, NO. 2, (245-265), Online publication date: 1-Mar-2004. Aus G, Becker C, Franzén S, Lilja H, Lodding P and Hugosson J (2004) Cumulative Prostate Cancer Risk Assessment with the Aid of the Free-to-Total Prostate Specific Antigen RatioEuropean Urology, 10.1016/j.eururo.2003.09.008, VOL. 45, NO. 2, (160-165), Online publication date: 1-Feb-2004. Morote Robles J (2004) Cuantificación de la isoforma compleja del antígeno prostático específico (PSAc). Un nuevo reto en la era PSAMedicina Clínica, 10.1016/S0025-7753(04)75315-4, VOL. 122, NO. 7, (256-258), Online publication date: 1-Jan-2004. Moul J (2004) Defining an Optimum PSA-Based Screening Strategy for Young Men Management of Prostate Cancer, 10.1007/978-1-59259-776-5_3, (37-56), . CATALONA W, BARTSCH G, RITTENHOUSE H, EVANS C, LINTON H, AMIRKHAN A, HORNINGER W, KLOCKER H and MIKOLAJCZYK S (2018) Serum Pro Prostate Specific Antigen Improves Cancer Detection Compared to Free and Complexed Prostate Specific Antigen in Men With Prostate Specific Antigen 2 to 4 Ng/MlJournal of Urology, VOL. 170, NO. 6, (2181-2185), Online publication date: 1-Dec-2003.PARTIN A, BRAWER M, BARTSCH G, HORNINGER W, TANEJA S, LEPOR H, BABAIAN R, CHILDS S, STAMEY T, FRITSCHE H, SOKOLL L, CHAN D, THIEL R and CHELI C (2018) Complexed Prostate Specific Antigen Improves Specificity for Prostate Cancer Detection: Results of a Prospective Multicenter Clinical TrialJournal of Urology, VOL. 170, NO. 5, (1787-1791), Online publication date: 1-Nov-2003. Moul J (2003) Population Screening for Prostate Cancer and Emerging Concepts for Young MenClinical Prostate Cancer, 10.3816/CGC.2003.n.015, VOL. 2, NO. 2, (87-97), Online publication date: 1-Sep-2003. Cramer S, Chang B, Rao A, Hawkins G, Zheng S, Wade W, Cooke R, Thomas L, Bleecker E, Catalona W, Sterling D, Meyers D, Ohar J and Xu J (2003) Association Between Genetic Polymorphisms in the Prostate-Specific Antigen Gene Promoter and Serum Prostate-Specific Antigen LevelsJNCI Journal of the National Cancer Institute, 10.1093/jnci/95.14.1044, VOL. 95, NO. 14, (1044-1053), Online publication date: 16-Jul-2003. Uzzo R, Pinover W, Horwitz E, Parlanti A, Mazzoni S, Raysor S, Mirchandani I, Greenberg R, Pollack A, Hanks G and Watkins-Bruner D (2003) Free prostate-specific antigen improves prostate cancer detection in a high-risk population of men with a normal total PSA and digitalrectal examinationUrology, 10.1016/S0090-4295(02)02524-4, VOL. 61, NO. 4, (754-759), Online publication date: 1-Apr-2003. Sokoll L, Chan D, Mikolajczyk S, Rittenhouse H, Evans C, Linton H, Mangold L, Mohr P, Bartsch G, Klocker H, Horninger W and Partin A (2003) Proenzyme psa for the early detection of prostate cancer in the 2.5–4.0 ng/ml total psa range: preliminary analysisUrology, 10.1016/S0090-4295(02)02398-1, VOL. 61, NO. 2, (274-276), Online publication date: 1-Feb-2003. Aus G, Becker C, Lilja H, Khatami A, Pihl C and Hugosson J (2009) Free‐to‐total prostate‐specific antigen ratio as a predictor of non‐organ‐confined prostate cancer (stage pT3)Scandinavian Journal of Urology and Nephrology, 10.1080/00365590310001746, VOL. 37, NO. 6, (466-470), Online publication date: 1-Jan-2003. Volume 168Issue 3September 2002Page: 922-925 Advertisement Copyright & Permissions© 2002 by American Urological Association, Inc.Keywordsprostate-specific antigenbiopsyprostatic neoplasmsMetricsAuthor Information Kimberly A. Roehl More articles by this author Jo ANN V. Antenor More articles by this author William J. Catalona More articles by this author Expand All Advertisement PDF downloadLoading ...